SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as the community discusses recent news and potential impacts from political decisions. Community members are focused on trade negotiations and tariff implications, as well as commentary around political figures and events. Broader discussions include market dynamics and potential financial strategies related to the stock.

Solana is a highly functional open source project that banks on blockchain technology’s permissionless nature to provide decentralized finance (DeFi) solutions. It is a layer 1 network that offers fast speeds and affordable costs. While the idea and initial work on the project began in 2017, Solana was officially launched in March 2020 by the Solana Foundation with headquarters in Geneva, Switzerland.

Solana

Solana is trending, with community members discussing its price action and potential. There is chatter about exchange-traded funds (ETFs), with Fidelity recently listing Solana. Some users are highlighting Solana's ecosystem and potential for future growth.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is trending as investors discuss its AI-powered biometric platform being deployed at Chicago O'Hare International Airport, sparking speculation about further airport security contracts and a potential TSA deal. The community is also focused on the company's large short interest and upcoming earnings, with some anticipating a squeeze. Bullish sentiment is fueled by the company's advancements in AI and its potential for significant growth within the national security sector.

Lumen Technologies, Inc. is an investment holding company, which engages in the provision of integrated communications to residential and business customers. It operates through the Business and Mass Markets segments. The Business segment provides products and services under four sales channels to enterprise and commercial customers. The Mass Markets segment focuses on consumer and small business customers. The company was founded in 1930 and is headquartered in Monroe, LA.

Lumen Technologies Inc

Lumen Technologies ($LUMN) is trending amid discussions about its role in AI infrastructure, particularly following a $200M deal with Palantir ($PLTR) to boost enterprise AI. Community members highlight Lumen's fiber optic network and partnerships with hyperscalers as key assets for AI data connectivity. Some are speculating on future earnings and potential government stakes in the company.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

$BALLIN is gaining attention, with community members highlighting its availability on Phantom Wallet and touting potential gains. The conversation centers around 'bags,' 'moonshots,' and 'rocket mode,' with many suggesting it's an opportune time to get in early. Some users are expressing concerns and caution.

USDC is a fully collateralized US dollar stablecoin. USDC is the bridge between dollars and trading on cryptocurrency exchanges. The technology behind CENTRE makes it possible to exchange value between people, businesses and financial institutions just like email between mail services and texts between SMS providers. We believe by removing artificial economic borders, we can create a more inclusive global economy.

USD Coin

USD Coin is trending amid discussions around stablecoin regulation and increasing adoption, particularly on Solana. Community members are highlighting its use in remittances, DeFi, and as a hedge against inflation in emerging markets. The meme coin BrokeCoin is also garnering attention within the USDC conversation.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around its resilient development team and utility-focused roadmap, highlighting staking opportunities and the Broke Perspective media platform. Despite market dips, the community expresses conviction, emphasizing long-term building and the potential for significant gains. Discussions also involve collaborations and support from other Solana-based projects.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

NBIS is trending due to a sharp rebound after a significant decline, with community members debating whether the bottom has been reached and discussing potential catalysts like earnings and partnerships. The stock's connection to the AI infrastructure boom and recent news regarding accelerated power hookups for data centers are also fueling interest. Bullish investors are highlighting the company's long-term potential and the increasing demand for AI infrastructure.

The 401jk (just kidding) meme is a satirical punch in the gut in the face of the concept of retirement and also the 401k. The 401k total holdings are valued at around $12 trillion USD and it is the most popular retirement savings plan in the US. As time passes forevermore true retirement, or as we like to call it real freedom will only become much harder and harder for people to attain.  Through meme fueled laser focus and cyperphunk ideology the 401jK meme retirement fund token and community aim to point out the absurdities of how rigged our current system is, and how only insiders and those with power are starting the benefit from the increased centralization of cryptocurrency.........while also aiming to flip the $12 trillion USD 401k system to achieve freedom before our backs and knees are breaking.

401jK

401JK is trending as community members rally around its narrative of disrupting traditional retirement plans, with many expressing bullish sentiment and highlighting the project's strong community and organic growth on the $SOL blockchain. Discussions revolve around the token's potential to reach new all-time highs and offer an alternative path to financial freedom, contrasting it with perceived flaws in the traditional 401(k) system. The community is actively promoting its message and celebrating milestones, with a focus on long-term vision rather than short-term gains.

MUSE

MUSE is trending as traders discuss its limited coin supply and potential for a squeeze, drawing comparisons to past rallies and other low-cap cryptos. Community members are actively watching volume, speculating on price movements, and highlighting its potential within the NFT space. Some believe that with increased exposure, MUSE could see significant gains.

statis crypto Watchlist

Bitcoin

Ethereum

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Revolution Medicines, Disc Medicine, and Regeneron Pharmaceuticals rose in after-hours trading on Thursday after the U.S. Food and Drug Administration (FDA) announced the first group of drugs selected for expedited review under its new National Priority Voucher pilot program.In after-hours trading on Thursday,&nbsp;<a href="https://stocktwits.com/symbol/RVMD">Revolution Medicines</a> jumped 9%,&nbsp;<a href="https://stocktwits.com/symbol/IRON">Disc Medicine</a> surged 17%, and&nbsp;<a href="https://stocktwits.com/symbol/REGN">Regeneron Pharmaceuticals</a> edged up 0.1%.FDA Names 9 Drugs For Accelerated ReviewThe FDA said nine products have been chosen for the fast-track review process, which shortens decision timelines from the usual 10–12 months to just one or two months once a complete application is filed.The selected drugs include Merck KGaA’s fertility treatment Pergoveris, Sanofi’s Type 1 diabetes therapy teplizumab, Regeneron’s gene therapy DB-OTO for congenital deafness, and ketamine for domestic manufacturing of a general anesthetic.&nbsp;Also on the list are Revolution Medicines’ RMC-6236 for pancreatic cancer, Disc Medicine’s bitopertin for porphyria, Achieve Life Sciences’ cytisinicline for nicotine vaping addiction, Dompe’s cenegermin-bkbj for blindness, and Augmentin XR for domestic manufacturing of a common antibiotic.FDA Commissioner Highlights Expedited Review EffortFDA Commissioner Marty Makary said the initiative could shorten FDA decision times from a year to "a matter of weeks” by moving promising or high-impact therapies to the front of the review line.Makary said some of the drugs selected for vouchers, including one that uses ketamine as a general anesthetic, will be manufactured in the United States. He described Regeneron’s DB-OTO, a gene therapy for congenital deafness, as “an exciting treatment,” noting that “some of these kids got normal hearing from this amazing treatment.”He added that this is just the first round of vouchers, with additional selections expected in the coming weeks.How Stocktwits Traders Reacted To FDA’s Fast-Track ListOn Stocktwits, retail sentiment toward Revolution Medicines was ‘extremely bullish’ with ‘extremely high’ message volume, while Disc Medicine saw ‘neutral’ sentiment amid similarly ‘extremely high’ activity, and Regeneron registered ‘neutral’ sentiment with ‘normal’ engagement levels.One&nbsp; user said they expect Regeneron shares to climb steadily, projecting the stock could reach the $800-$900 range within two years.&nbsp;<stembedurl>https://stocktwits.com/Iwannagofast1/message/632653980</stembedurl>Another bullish trader suggested Revolution Medicines could be an attractive takeover candidate, potentially fetching twice its current value.<stembedurl>https://stocktwits.com/ChessGM/message/632555600</stembedurl>So far this year, Revolution Medicines shares have gained 14%, Disc Medicine is up 17%, while Regeneron has declined 20%.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the FDA (United States Food and Drug Administration) logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Revolution Medicines, Disc Medicine, Regeneron Stocks Jump After-Hours As FDA Fast-Tracks 9 Drugs Under New Review Program

The FDA’s new National Priority Voucher pilot helps with faster drug reviews, cutting timelines from nearly a year to weeks.

Equity

Wall Street Analysts Believe Revolution Medicines (RVMD) Could Rally 90.58%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 90.6% in Revolution Medicines (RVMD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Royalty Pharma Plc. (RPRX) on Tuesday announced a $2 billion funding arrangement with Revolution Medicines (RVMD), aimed at supporting the latter’s plans for global development of its investigational cancer drug Daraxonrasib.As per the <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.revmed.com/news-releases/news-release-details/revolution-medicines-enters-2-billion-flexible-funding-agreement">arrangement</a>, Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured loan of up to $750 million.Synthetic royalty financing is a type of funding where a company sells a portion of its future revenue stream in exchange for upfront capital, without relinquishing ownership of the underlying asset.Funds worth $1.25 billion will be awarded in five tranches upon Revolution Medicines hitting certain product development milestones. The first two $250 million tranches, totaling $500 million, are payable prior to the FDA’s approval of Daraxonrasib, and royalty obligations begin only after that.The funds, Royalty Pharma said, will support Revolution Medicines’ plans for global development and commercialization of Daraxonrasib and its pipeline programs for patients with RAS-addicted cancers.Daraxonrasib is an experimental drug in late-stage development for RAS mutant pancreatic cancer and non-small cell lung cancer (NSCLC). RAS is one of the most commonly mutated genes in human cancer, and the drug works by targeting RAS proteins.In the U.S., approximately 56,000 patients are diagnosed with RAS-driven pancreatic cancer annually, while approximately 60,000 patients are diagnosed with RAS-driven NSCLC annually, Royalty Pharma said.Revolution Medicines expects late-stage trial results for Daraxonrasib in pancreatic cancer in 2026.Revolution Medicines CEO Mark A. Goldsmith said that the funding agreement “significantly increases” the financial resources the company can deploy.The company had cash, cash equivalents, and marketable securities of $2.1 billion as of March 31. The company said on Tuesday that it is removing its cash runway end date guidance owing to the new funding agreement.On Stocktwits, retail sentiment around RVMD fell from ‘bullish’ to ‘neutral’ territory over the past 24 hours while message volume increased from ‘low’ to ‘high’ levels.<figure class="image"><img style="aspect-ratio:626/64;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_9_43_59_AM_png_4b2fb6ec49.webp" alt="RVMD's Sentiment Meter and Message Volume as of 9:40 a.m. ET on June 24, 2025 | Source: Stocktwits" width="626" height="64"><figcaption>RVMD's Sentiment Meter and Message Volume as of 9:40 a.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure>As for RPRX, retail sentiment stayed unmoved within ‘bearish’ territory over the past 24 hours while message volume improved from ‘low’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:631/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_24_at_9_45_20_AM_png_2660096f57.webp" alt="RPRX's Sentiment Meter and Message Volume as of 9:45 a.m. ET on June 24, 2025 | Source: Stocktwits" width="631" height="66"><figcaption>RPRX's Sentiment Meter and Message Volume as of 9:45 a.m. ET on June 24, 2025 | Source: Stocktwits</figcaption></figure> RVMD is trading nearly 2% lower on Tuesday morning.While <a href="https://stocktwits.com/symbol/RVMD">RVMD stock</a> is down by about 10% this year, <a href="https://stocktwits.com/symbol/RPRX">RPRX</a> is up by about 41%.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/verizon-ai-powered-overhaul-of-customer-support-draws-retail-praise/chm49CNRR34">Verizon’s AI-Powered Overhaul Of Customer Support Draws Retail Praise</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Revolution Medicines company logo is seen displayed on a smartphone screen. (Photo Illustration by Piotr Swat/SOPA Images/LightRocket via Getty Images)

Revolution Medicines To Get Up To $2B For Development Of Cancer Drug From Royalty Pharma

Royalty Pharma will provide up to $1.25 billion to Revolution Medicines in exchange for a synthetic royalty on annual worldwide net sales of Daraxonrasib for a term of 15 years and a senior secured loan of up to $750 million.

Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Revolution Medicines (RVMD) and Personalis (PSNL)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Amphastar Pharmaceuticals (AMPH Research Report), Revolution Medicines...

Outperform Rating with Raised Price Target for Revolution Medicines Amid Promising Oncology Trials

Analyst Jonathan Chang from Leerink Partners maintained a Buy rating on Revolution Medicines (RVMD Research Report) and increased the price targe...

Buy Rating Affirmed for Revolution Medicines on Promising RMC-6236 Clinical Data and Market Potential

Leerink Partners analyst Jonathan Chang has maintained their bullish stance on RVMD stock, giving a Buy rating today. Jonathan Chang has given his...

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD)

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Revolution Medicines, Inc. (NASDAQ: RVMD) SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder...

What's Going On With Revolution Medicines Stock?

Revolution Medicines announced the publication of a peer-reviewed research paper in 'Cancer Discovery' detailing the discovery and preclinical to clinical translation for RMC-6236 on Monday. The...

Futures On Edge Ahead Of Critical CPI Report

Futures On Edge Ahead Of Critical CPI Report

 Futures are up small before the March CPI data was expected to show further moderation in price pressures following stronger readings at the...

Revolution Medicines, Inc. (NASDAQ:RVMD) Receives $38.80 Consensus Target Price from Analysts

Revolution Medicines, Inc. (NASDAQ:RVMD - Get Free Report) has been given an average recommendation of "Buy" by the ten brokerages that are presently covering the firm, Marketbeat reports. Ten...

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Current Price	$53.44
Prev Close	$52.98
Open	$53.15
Dividend Yield	0.00%
50-Day Moving Average	$43.79
Beta	1.19
Avg. Volume	2.25M
PE Ratio	-11.86

52-Week High	$62.40
52-Week Low	$29.17
Market Capitalization	$9.99B
EPS (Annual)	-$3.58
Price to Book	5.35
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

RVMD
Revolution Medicines Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RVMD News

RVMDRevolution Medicines Inc